↓ Skip to main content

Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis

Overview of attention for article published in BMC Pulmonary Medicine, November 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
8 tweeters
googleplus
1 Google+ user

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
50 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis
Published in
BMC Pulmonary Medicine, November 2015
DOI 10.1186/s12890-015-0138-4
Pubmed ID
Authors

David A Scott, Bethan Woods, Juliette C Thompson, James F Clark, Neil Hawkins, Mike Chambers, Bartolome R. Celli, Peter Calverley

Abstract

Increasing evidence suggests pharmacological treatments may impact on overall survival in Chronic Obstructive Pulmonary Disease (COPD) patients. Individual clinical trials are rarely powered to detect mortality differences between treatments and may not include all treatment options relevant to healthcare decision makers. A systematic review was conducted to identify RCTs of COPD treatments reporting mortality; evidence was synthesised using network meta-analysis (NMA). The analysis included 40 RCTs; a quantitative indirect comparison between 14 treatments using data from 55,220 patients was conducted. The analysis reported two treatments reducing all-cause mortality; salmeterol/fluticasone propionate combination (SFC) was associated with a reduction in mortality versus placebo in the fixed effects (HR 0.79; 95 % Crl 0.67, 0.94) but not the random effects model (0.79; 0.56, 1.09). Indacaterol was associated with a reduction in mortality versus placebo in fixed (0.28; 0.08 to 0.85) and random effects (0.29; 0.08, 0.89) models. Mean estimates and credible intervals for hazard ratios for indacaterol versus placebo are based on a small number of events; estimates may change when the results of future studies are included. These results were maintained across a variety of assumptions and provide evidence that SFC and indacaterol may lead to improved survival in COPD patients. Results of an NMA of COPD treatments suggest that SFC and indacaterol may reduce mortality. Further research is warranted to strengthen this conclusion.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
United States 1 2%
Unknown 48 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 14%
Other 7 14%
Student > Postgraduate 6 12%
Student > Ph. D. Student 5 10%
Student > Bachelor 4 8%
Other 11 22%
Unknown 10 20%
Readers by discipline Count As %
Medicine and Dentistry 25 50%
Pharmacology, Toxicology and Pharmaceutical Science 5 10%
Nursing and Health Professions 2 4%
Agricultural and Biological Sciences 2 4%
Social Sciences 1 2%
Other 3 6%
Unknown 12 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 November 2015.
All research outputs
#3,997,467
of 16,623,170 outputs
Outputs from BMC Pulmonary Medicine
#238
of 1,344 outputs
Outputs of similar age
#67,096
of 286,731 outputs
Outputs of similar age from BMC Pulmonary Medicine
#34
of 134 outputs
Altmetric has tracked 16,623,170 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,344 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,731 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 134 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.